LENZ Therapeutics (LENZ) grants director 22,100 stock options at $6.63

Rhea-AI Filing Summary

LENZ Therapeutics, Inc. reported that director Shelley B. Thunen received a grant of stock options for 22,100 shares of common stock at an exercise price of $6.63 per share. These options expire on June 15, 2036 and will vest 100% on June 15, 2027 or the next annual stockholder meeting, provided she continues as an Outside Director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Thunen Shelley B

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,100	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 22,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 22,100 options Exercise price: $6.63 per share Expiration date: June 15, 2036 +2 more

5 metrics

Stock options granted 22,100 options Grant to director Shelley B. Thunen

Exercise price $6.63 per share Strike price for the 22,100 options

Expiration date June 15, 2036 Option term end

Vesting date June 15, 2027 or next annual meeting 100% vesting, subject to continued Outside Director service

Post-transaction derivative holdings 22,100 options Total options held directly after the grant

Key Terms

Stock Option (right to buy), Outside Director, annual meeting of stockholders

3 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Outside Director financial

"Subject to the Reporting Person continuing to be an Outside Director"

annual meeting of stockholders financial

"on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thunen Shelley B

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.63	06/15/2026		A		22,100		(1)	06/15/2036	Common Stock	22,100	$0	22,100	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LENZ (LENZ) report for Shelley B. Thunen?

LENZ reported that director Shelley B. Thunen received a grant of stock options for 22,100 shares of common stock. The options were awarded as compensation, not purchased on the open market, and give her the right to buy shares at a fixed exercise price.

What are the key terms of the 22,100 LENZ stock options granted to Shelley B. Thunen?

The grant covers 22,100 stock options with an exercise price of $6.63 per share and an expiration date of June 15, 2036. Each option relates to one share of LENZ common stock, giving the director the right to purchase at that fixed price in the future.

When do Shelley B. Thunen’s LENZ stock options vest?

All 22,100 options will vest 100% on the earlier of June 15, 2027 or the date of LENZ’s next annual meeting of stockholders. Vesting requires that she continue serving as an Outside Director under the company’s Outside Director Compensation Policy through the relevant vesting date.

Is the LENZ Form 4 transaction an open-market purchase or a compensation award?

The Form 4 shows a compensation award, not an open-market purchase. The transaction code is “A,” indicating a grant or award acquisition of stock options, with a transaction price of $0.00 and a separate exercise price of $6.63 per share for future potential purchases.

How many LENZ derivative securities does Shelley B. Thunen hold after this grant?

After this grant, Shelley B. Thunen holds 22,100 stock options directly, according to the reported holdings following the transaction. Each option is exercisable for one share of LENZ common stock, subject to the vesting conditions and the expiration date described in the filing.